CY1113680T1 - Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10 - Google Patents

Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10

Info

Publication number
CY1113680T1
CY1113680T1 CY20121101246T CY121101246T CY1113680T1 CY 1113680 T1 CY1113680 T1 CY 1113680T1 CY 20121101246 T CY20121101246 T CY 20121101246T CY 121101246 T CY121101246 T CY 121101246T CY 1113680 T1 CY1113680 T1 CY 1113680T1
Authority
CY
Cyprus
Prior art keywords
phosphosteration
inhibitors
pyrazine compounds
compounds
methods
Prior art date
Application number
CY20121101246T
Other languages
Greek (el)
English (en)
Inventor
Jennifer R Allen
Matthew P Bourbeau
Ning Chen
Essa Hu
Roxanne Kunz
Shannon Rumfelt
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1113680T1 publication Critical patent/CY1113680T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20121101246T 2008-11-14 2012-12-21 Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10 CY1113680T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11456708P 2008-11-14 2008-11-14
US16621209P 2009-04-02 2009-04-02
EP09752705A EP2364308B1 (en) 2008-11-14 2009-11-16 Pyrazine compounds as phosphodiesterase 10 inhibitors

Publications (1)

Publication Number Publication Date
CY1113680T1 true CY1113680T1 (el) 2016-06-22

Family

ID=41478512

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101246T CY1113680T1 (el) 2008-11-14 2012-12-21 Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10

Country Status (30)

Country Link
US (4) US8053438B2 (enExample)
EP (1) EP2364308B1 (enExample)
JP (1) JP5746972B2 (enExample)
KR (1) KR20110083746A (enExample)
CN (1) CN102300860B (enExample)
AR (1) AR074358A1 (enExample)
AU (1) AU2009313768B2 (enExample)
BR (1) BRPI0922095A2 (enExample)
CA (1) CA2742993C (enExample)
CL (1) CL2011001094A1 (enExample)
CO (1) CO6382157A2 (enExample)
CR (1) CR20110326A (enExample)
CY (1) CY1113680T1 (enExample)
DK (1) DK2364308T3 (enExample)
EA (1) EA019206B1 (enExample)
ES (1) ES2397218T3 (enExample)
HR (1) HRP20130054T1 (enExample)
IL (1) IL212687A0 (enExample)
MA (1) MA32889B1 (enExample)
MX (1) MX2011005100A (enExample)
NZ (1) NZ592508A (enExample)
PE (1) PE20110581A1 (enExample)
PL (1) PL2364308T3 (enExample)
PT (1) PT2364308E (enExample)
RS (1) RS52598B (enExample)
SI (1) SI2364308T1 (enExample)
SM (1) SMT201200061B (enExample)
TN (1) TN2011000221A1 (enExample)
TW (1) TWI396689B (enExample)
WO (1) WO2010057121A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
JP2012512255A (ja) * 2008-12-17 2012-05-31 アムジエン・インコーポレーテツド ホスホジエステラーゼ10阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物
US8354411B2 (en) 2009-02-05 2013-01-15 Takeda Pharmaceutical Company Limited 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
WO2010132442A1 (en) * 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
JP5780528B2 (ja) 2010-02-19 2015-09-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
WO2012018058A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
EP3357915A1 (en) 2010-11-19 2018-08-08 Ligand Pharmaceuticals Inc. Heterocycle amines with anti-inflammatory activity
WO2012096929A2 (en) 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9029388B2 (en) 2011-03-16 2015-05-12 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
EP2890370B1 (en) * 2012-08-31 2019-10-09 The Regents of the University of California Agents useful for treating obesity, diabetes and related disorders
CN102911135B (zh) * 2012-10-18 2016-01-13 内蒙古工业大学 2-巯基苯并噻唑类衍生物的合成方法
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014142322A1 (ja) 2013-03-15 2014-09-18 第一三共株式会社 ベンゾチオフェン誘導体
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR20160092991A (ko) 2013-09-27 2016-08-05 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104649882A (zh) * 2015-02-11 2015-05-27 南通恒盛精细化工有限公司 一种磷酸二酯酶抑制剂的中间体制备工艺
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
KR20180052635A (ko) * 2015-09-18 2018-05-18 가켄 세이야쿠 가부시키가이샤 바이아릴 유도체 및 이를 포함하는 약제
US11453674B2 (en) 2018-01-19 2022-09-27 Evopoint Biosciences Co., Ltd. Heterocyclic compound, preparation method and use thereof in medicine
CN109020977B (zh) * 2018-10-26 2020-11-13 安庆奇创药业有限公司 一种Acalabrutinib的制备方法
CN116583577B (zh) 2020-12-17 2025-10-21 默克专利股份有限公司 杂芳族异硫氰酸酯
CN113929598A (zh) * 2021-11-24 2022-01-14 上海吉奉生物科技有限公司 一种(s)-2-叔丁氧羰基氨基-3-(4,4-二氟环己基)丙酸的合成方法
WO2023217156A1 (zh) * 2022-05-09 2023-11-16 浙江同源康医药股份有限公司 多环类化合物及其用途
CN115894181A (zh) * 2022-09-30 2023-04-04 渭南高新区海泰新型电子材料有限责任公司 一种环己烯基环己基二氟苯类液晶化合物的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ATE392896T1 (de) 2003-04-04 2008-05-15 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6- tetrahydropyridin-derivate als serotonin- wiederaufnahme-hemmer
DE10337942A1 (de) 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
KR100907354B1 (ko) * 2004-05-18 2009-07-10 쉐링 코포레이션 Pde4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸
WO2005120514A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
US20080227783A1 (en) 2005-08-02 2008-09-18 Irm Llc 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
CA2650976A1 (en) * 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EP2125786B1 (en) * 2006-12-21 2011-03-16 Pfizer Products Inc. Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline
KR20100089090A (ko) 2007-10-25 2010-08-11 아스트라제네카 아베 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 gpr119 작동약 및 이의 용도

Also Published As

Publication number Publication date
SMT201200061B (it) 2013-01-14
JP2012508776A (ja) 2012-04-12
CA2742993A1 (en) 2010-05-20
US20110160202A1 (en) 2011-06-30
CA2742993C (en) 2015-01-20
HRP20130054T1 (hr) 2013-02-28
CL2011001094A1 (es) 2011-11-11
MX2011005100A (es) 2011-05-30
US8329700B2 (en) 2012-12-11
PE20110581A1 (es) 2011-09-03
KR20110083746A (ko) 2011-07-20
US20110160182A1 (en) 2011-06-30
SI2364308T1 (sl) 2013-01-31
PT2364308E (pt) 2013-01-08
US20100137278A1 (en) 2010-06-03
BRPI0922095A2 (pt) 2019-09-24
WO2010057121A1 (en) 2010-05-20
US20120277209A1 (en) 2012-11-01
AU2009313768A1 (en) 2010-05-20
CN102300860A (zh) 2011-12-28
RS52598B (sr) 2013-04-30
CO6382157A2 (es) 2012-02-15
DK2364308T3 (da) 2013-02-04
AU2009313768B2 (en) 2013-01-10
TW201030006A (en) 2010-08-16
NZ592508A (en) 2013-04-26
MA32889B1 (fr) 2011-12-01
TN2011000221A1 (en) 2012-12-17
EP2364308B1 (en) 2012-10-24
EA201100748A1 (ru) 2011-10-31
ES2397218T3 (es) 2013-03-05
US8247418B2 (en) 2012-08-21
HK1161251A1 (en) 2012-08-24
EP2364308A1 (en) 2011-09-14
AR074358A1 (es) 2011-01-12
US8053438B2 (en) 2011-11-08
PL2364308T3 (pl) 2013-03-29
EA019206B1 (ru) 2014-01-30
IL212687A0 (en) 2011-07-31
CR20110326A (es) 2011-07-28
TWI396689B (zh) 2013-05-21
JP5746972B2 (ja) 2015-07-08
CN102300860B (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
CY1113680T1 (el) Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201100426A1 (ru) Бициклические ингибиторы киназы
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
PH12012502212A1 (en) Nitrogen heterocyclic compounds usefulas pde10 inhibitors
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
MX2009013077A (es) Derivados dde benzoxazolona.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
CY1115107T1 (el) ΕΝΩΣΕΙΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΩΝ ΙΜΙΔΑΖΟ[1,2-b]ΠΥΡΙΔΑΖΙΝΩΝ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ TRK
EA200970738A1 (ru) Ингибиторы активности akt
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
UA112795C2 (uk) Біциклічні піразинонові похідні
PH12013500274A1 (en) Heteroaryls and uses thereof
IN2012DN01983A (enExample)
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2010007392A (es) Antagonistas de trpa1.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.